info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Middle East & Africa Blood Coagulants Market Research Report Information, By Types (Coagulation Factor, others), Indication (Haemophilia, Surgery, other Bleeding Disorders) -Forecast till 2030


ID: MRFR/Pharma/2027-CR | 53 Pages | Author: Kinjoll Dey| July 2017

Middle East & Africa Blood Coagulants Market Overview


The Middle East & Africa Blood Coagulants Market is expected to grow USD 2.77 Billion at a CAGR 6.70% during the forcast period 2023 to 2030. Coagulation is the process, by which blood changes from a liquid to a gel, forming a blood clot. In general terms, coagulation is a process in which the blood forms clots to block and then heal a lesion/wound/cut and stop the bleeding.


Middle East & Africa Blood Coagulants Market


The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. 


In the Middle East and Sub-Saharan Africa, bleeding disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment. As per the study published in Blood Coagulation Fibrinolysis journal, 2016, it is reported that in the Yaoundé Hemophilia Treatment Center (HTC) of Cameroon multiple cases of hemophilia and von willebrand disease (VWD) have been registered According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH), in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years A  research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia in Saudi Arabia and most dominant in male patients: 1 : 5000 to 10,000. Whereas, prevalence rate of hemophilia B: 1: 34,500 male patients


The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. On the other hand, there are certain factors that also hinder the growth of this market such as lack of R&D capabilities in the regions, presence of counterfeit drugs, and lack of awareness in most of the parts of developing and underdeveloped countries in the region.


Figure- MEA blood coagulants market, by Country 2016 (%) MEA blood coagulants market


Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis 


Intended Audience:



  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors 


Research Methodology:


MEA blood coagulants market research


Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis 


Middle East & Africa Blood Coagulants Market Segmentation    


The Middle East & Africa blood coagulants market is segmented on the basis of types, indications, and by country.


On the basis of types, the Middle East & Africa blood coagulants market is segmented into coagulation factor and others. Coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.


On the basis of indication, the Middle East & Africa blood coagulants market is segmented into haemophilia, surgery, other bleeding disorders, and others. Haemophilia is further divided into haemophilia A and haemophilia B.


On the basis of country, the Middle East & Africa blood coagulants market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of Middle East & Africa. 


Middle East & Africa Blood Coagulants Market Regional Analysis


The Middle East & Africa blood coagulants market is segmented on the basis of countries into Saudi Arabia (KSA), United Arab Emirates (UAE), Qatar, Oman, Kuwait, Egypt, and rest of Middle East & Africa. Saudi Arabia account for the largest market share of the Middle East & Africa blood coagulants market by countries in 2016. The large share is majorly attributed to increasing prevalence of the haemophilia disease in this country, high usage of the expensive recombinant coagulation factors for the treatment, and high disposable income of the population, and better healthcare facilities in this country. 


Key Findings:



  • Hemophilia segment dominates the market with nearly 45.5% share of the MEA market

  • MEA coagulation factor market is projected to reach about USD 141.68 million by 2023

  • MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016

  • UAE is the fastest growing region in the MEA blood coagulants market with 10.1% CAGR during 2017 to 2023


Key Players for Middle East & Africa Blood Coagulants Market


Some of the major players in Middle East & Africa blood coagulants market are: 



  • Pfizer Inc. (U.S.)

  • Bayer AG (Germany)

  • Novo Nordisk AS (Dernmark)

  • Shire (Republic of Ireland)

  • SOBI (Sweden)

  • Octapharma (Switzerland)

  • CSL Limited (Australia)

Report Attribute/Metric Details
  Market Size  2.77 Billion
  CAGR  6.70%
  Base Year   2022
  Forecast Period   2023-2030
  Historical Data   2021
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered  Types and Indication 
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia).
  Key Market Opportunities Increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage
  Key Market Drivers Awareness programs for bleeding disorders.


Frequently Asked Questions (FAQ) :

Middle East & Africa blood coagulants market is projected to grow at approximately 6.70% CAGR during the assessment period (2023-2030).

Middle East & Africa blood coagulants market is estimated to reach a valuation of approx. USD 2.77 Billion by the end of 2030.

Rising funding from the private & public organizations, proliferation of healthcare insurance coverage, and awareness programs for bleeding disorders, are major tailwinds pushing the growth of the Middle East & Africa blood coagulants market.

Lack of R&D capabilities and awareness in most of the parts of developing and underdeveloped countries and presence of counterfeit drugs in the regions, are major growth impeder for the Middle East & Africa blood coagulants market.

Saudi Arabia holds the largest share in the Middle East & Africa blood coagulants market.

Pfizer Inc. (U.S.), Novo Nordisk AS (Denmark), Bayer AG (Germany), SOBI (Sweden), Shire (Republic of Ireland), CSL Limited (Australia), and Octapharma (Switzerland), are some of the top players operating in the Middle East & Africa blood coagulants market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.